Advanced search
Publication Cover
Biomarkers in Medicine Volume 3, 2009 - Issue 5
Submit an article Journal homepage
77
Views
1
CrossRef citations to date
0
Altmetric
Theme: Biomarkers: paving the way for better stratification in heart failure - Perspective

Biomarkers of Risk Stratification in Congestive Heart Failure: North American View

WH Wilson TangSection of Heart Failure & Cardiac Transplantation Medicine,Department of Cardiovascular Medicine,Heart & Vascular Institute,The Cleveland Clinic,9500 Euclid Avenue,Desk J3–4,Cleveland,OH 44195,USA. Correspondence[email protected]
Pages 443-452 | Published online: 08 Oct 2009

Bibliography

  • Velagaleti RS , PencinaMJ, MurabitoJMet al. : Long-term trends in the incidence of heart failure after myocardial infarction.Circulation118, 2057–2062 (2008).
  • Jessup M , AbrahamWT, CaseyDEet al. : 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.Circulation119, 1977–2016 (2009).
  • deFilippi CR , SeligerSL: Biomarkers for prognostication after acute coronary syndromes: new times and statistics.J. Am. Coll. Cardiol.54, 365–367 (2009).
  • Kalantar-Zadeh K , BlockG, HorwichT, FonarowGC: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure.J. Am. Coll. Cardiol.43, 1439–1444 (2004).
  • Tang WH , FrancisGS, MorrowDAet al. : National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure.Circulation116, E99–E109 (2007).
  • Heart Failure Society of America: Evaluation of patients for ventricular dysfunction and heart failure. J. Card. Fail.12, E16–E25 (2006).
  • Maisel AS , KrishnaswamyP, NowakRMet al. : Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N. Engl. J. Med.347, 161–167 (2002).
  • Januzzi JL Jr, Camargo CA, Anwaruddin S et al.: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am. J. Cardiol.95, 948–954 (2005).
  • Fonarow GC , PeacockWF, PhillipsCO, GivertzMM, LopatinM: Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.J. Am. Coll. Cardiol.49, 1943–1950 (2007).
  • Januzzi JL Jr, Sakhuja R, O‘Donoghue M et al.: Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med.166, 315–320 (2006).
  • Moe GW , HowlettJ, JanuzziJL, ZowallH: N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study.Circulation115, 3103–3110 (2007).
  • Mueller C , ScholerA, Laule-KilianKet al. : Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.N. Engl. J. Med.350, 647–654 (2004).
  • Singer AJ , BirkhahnRH, GussDet al. : Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial BNP testing on patient management.Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.108.826685 (2009) (Epub ahead of print).
  • Schneider HG , LamL, LokugeAet al. : B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial.Ann. Intern. Med.150, 365–371 (2009).
  • O‘Neill JO , Bott-SilvermanCE, McRaeAT 3rd et al.: B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am. Heart J.149, 363–369 (2005).
  • Shah MR , HasselbladV, TasissaGet al. : Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial).Am. J. Cardiol.100, 1427–1433 (2007).
  • Mehra MR , UberPA, ParkMHet al. : Obesity and suppressed B-type natriuretic peptide levels in heart failure.J. Am. Coll. Cardiol.43, 1590–1595 (2004).
  • Taylor JA , ChristensonRH, RaoK, JorgeM, GottliebSS: B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures.Am. Heart J.152, 1071–1076 (2006).
  • Troughton RW , PriorDL, PereiraJJet al. : Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.J. Am. Coll. Cardiol.43, 416–422 (2004).
  • Tang WH , GirodJP, LeeMJet al. : Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure.Circulation108, 2964–2966 (2003).
  • James KB , TroughtonRW, FeldschuhJ, SoltisD, ThomasD, Fouad-TaraziF: Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study.Am. Heart J.150, 984 (2005).
  • van Kimmenade RR , JanuzziJL Jr, Bakker JA et al.: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol.53, 884–890 (2009).
  • Hogenhuis J , VoorsAA, JaarsmaT, HillegeHL, BoomsmaF, van Veldhuisen DJ: Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur. J. Heart Fail.7, 81–86 (2005).
  • Pfisterer M , BuserP, RickliHet al. : BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.JAMA301, 383–392 (2009).
  • Jourdain P , JondeauG, FunckFet al. : Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study.J. Am. Coll. Cardiol.49, 1733–1739 (2007).
  • Peacock WF t, De Marco T, Fonarow GC et al.: Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med.358, 2117–2126 (2008).
  • Cardinale D , SandriMT, ColomboAet al. : Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.Circulation109, 2749–2754 (2004).
  • Cardinale D , ColomboA, SandriMTet al. : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.Circulation114, 2474–2481 (2006).
  • Fonarow GC , AdamsKF Jr, Abraham WT, Yancy CW, Boscardin WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293, 572–580 (2005).
  • Filippatos G , RossiJ, Lloyd-JonesDMet al. : Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.J. Card. Fail.13, 360–364 (2007).
  • Forman DE , ButlerJ, WangYet al. : Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.J. Am. Coll. Cardiol.43, 61–67 (2004).
  • Gottlieb SS , AbrahamW, ButlerJet al. : The prognostic importance of different definitions of worsening renal function in congestive heart failure.J. Card. Fail.8, 136–141 (2002).
  • Pilz S , MarzW, WellnitzBet al. : Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography.J. Clin. Endocrinol. Metab.93, 3927–3935 (2008).
  • Gheorghiade M , RossiJS, CottsWet al. : Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial.Arch. Intern. Med.167, 1998–2005 (2007).
  • Packer M , LeeWH, KesslerPD, MedinaN, YushakM, GottliebSS: Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure.J. Am. Coll. Cardiol.10, 837–844 (1987).
  • Rossi J , BayramM, UdelsonJEet al. : Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.Acute Card. Care9, 82–86 (2007).
  • Konstam MA , GheorghiadeM, BurnettJC Jr et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA297, 1319–1331 (2007).
  • Paterna S , Di Pasquale P, Parrinello G et al.: Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J. Am. Coll. Cardiol.45, 1997–2003 (2005).
  • Anand IS , FloreaVG: High output cardiac failure.Curr. Treat. Options Cardiovasc. Med.3, 151–159 (2001).
  • Tang WH : Anemia in heart failure: current evidence and challenges.Rev. Cardiovasc. Med.8, 78–86 (2007).
  • Tang WH , TongW, JainA, FrancisGS, HarrisCM, YoungJB: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.J. Am. Coll. Cardiol.51, 569–576 (2008).
  • Felker GM , AllenLA, PocockSJet al. : Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM program and the Duke databank.J. Am. Coll. Cardiol.50, 40–47 (2007).
  • Wood P : The erythrocyte sedimentation rate in diseases of the heart.Q. J. Med.5, 1–19 (1939).
  • Petersen JW , FelkerGM: Inflammatory biomarkers in heart failure.Congest. Heart Fail.12, 324–328 (2006).
  • Anand IS , LatiniR, FloreaVGet al. : C-reactive protein in heart failure: prognostic value and the effect of valsartan.Circulation112, 1428–1434 (2005).
  • Tang WH , ShresthaK, Van Lente F et al.: Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am. J. Cardiol.101, 370–373 (2008).
  • Tang WH , BrennanML, PhilipKet al. : Plasma myeloperoxidase levels in patients with chronic heart failure.Am. J. Cardiol.98, 796–799 (2006).
  • Tang WH , TongW, TroughtonRWet al. : Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.J. Am. Coll. Cardiol.49, 2364–2370 (2007).
  • Mocatta TJ , PilbrowAP, CameronVAet al. : Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.J. Am. Coll. Cardiol.49, 1993–2000 (2007).
  • Tang WH , TongW, TroughtonRWet al. : Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.J. Am. Coll. Cardiol.49, 2364–2370 (2007).
  • Kardys I , KnetschAM, BleuminkGSet al. : C-reactive protein and risk of heart failure. The Rotterdam Study.Am. Heart J.152, 514–520 (2006).
  • Ng LL , PathikB, LokeIW, SquireIB, DaviesJE: Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.Am. Heart J.152, 94–101 (2006).
  • Tang WH , KatzR, BrennanMLet al. : Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure.Am. J. Cardiol.103, 1269–1274 (2009).
  • Vasan RS , SullivanLM, RoubenoffRet al. : Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.Circulation107, 1486–1491 (2003).
  • Leyva F , AnkerSD, GodslandIFet al. : Uric acid in chronic heart failure: a marker of chronic inflammation.Eur. Heart J.19, 1814–1822 (1998).
  • Anker SD , DoehnerW, RauchhausMet al. : Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.Circulation107, 1991–1997 (2003).
  • Hare JM , MangalB, BrownJet al. : Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.J. Am. Coll. Cardiol.51, 2301–2309 (2008).
  • Crispell KA , HansonEL, CoatesK, ToyW, HershbergerRE: Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy.J. Am. Coll. Cardiol.39, 1503–1507 (2002).
  • Tang WH : Natriuretic peptide measurements in managing heart failure: in theory and in practice.Circ. Heart Fail.2, 380–381 (2009).
  • Boisot S , BeedeJ, IsaksonSet al. : Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.J. Card. Fail.14, 732–738 (2008).
  • Januzzi JL Jr, Peacock WF, Maisel AS et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol.50, 607–613 (2007).
  • Rehman SU , MuellerT, JanuzziJL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol.52, 1458–1465 (2008).
  • Milting H , EllinghausP, SeewaldMet al. : Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.J. Heart Lung Transplant.27, 589–596 (2008).
  • van Kimmenade RR , JanuzziJL Jr, Ellinor PT et al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol.48, 1217–1224 (2006).
  • Radauceanu A , DuckiC, VirionJMet al. : Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure.J. Card. Fail.14, 467–474 (2008).
  • Kempf T , von Haehling S, Peter T et al.: Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol.50, 1054–1060 (2007).
  • Dieplinger B , GegenhuberA, HaltmayerM, MuellerT: Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in shortness-of-breath patients.Heart doi: 10.1136/hrt.2009.170696 (2009) (Epub ahead of print).
  • Voors AA , von Haehling S, Anker SD et al.: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur. Heart J.30, 1187–1194 (2009).
  • Tang WH , WangZ, ChoL, BrennanDM, HazenSL: Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.J. Am. Coll. Cardiol.53, 2061–2067 (2009).
  • Tang WH , TongW, ShresthaKet al. : Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure.Eur. Heart J.29, 2506–2513 (2008).
  • Wei YJ , HuangYX, ZhangXLet al. : Apolipoprotein D as a novel marker in human end-stage heart failure: a preliminary study.Biomarkers13, 535–548 (2008).
  • Wedel H , McMurrayJJ, LindbergMet al. : Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide.Eur. J. Heart Fail.11, 281–291 (2009).
  • Hershberger RE , LindenfeldJ, MestroniL, SeidmanCE, TaylorMR, TowbinJA: Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline.J. Card. Fail.15, 83–97 (2009).
  • Liggett SB , Mialet-PerezJ, Thaneemit-ChenSet al. : A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure.Proc. Natl Acad. Sci. USA103, 11288–11293 (2006).
  • Taylor MR , SlavovD, HumphreyKet al. : Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.Pharmacogenet. Genomics19, 35–43 (2009).
  • McNamara DM , HolubkovR, PostavaLet al. : Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.J. Am. Coll. Cardiol.44, 2019–2026 (2004).
  • McKie PM , RodehefferRJ, CataliottiAet al. : Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.Hypertension47, 874–880 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.